SCHEMBL6462972

SCHEMBL6462972

NC(=O)CCc1ccc(N2Cc3ccccc3C2=O)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.57
NPC1 O15118 4/20 0.57
PKM P14618 3/20 0.56
SMN1; SMN2 Q16637 3/20 0.53
KMT2A Q03164 3/20 0.53
TP53 P04637 2/20 0.53
GAA P10253 2/20 0.53
MEN1 O00255 1/20 0.53
LMNA P02545 1/20 0.53
CYP2D6 P10635 1/20 0.53
CYP2C19 P33261 1/20 0.53
PGR P06401 1/20 0.53
CYP3A4 P08684 1/20 0.53
NFKB1 P19838 1/20 0.53
DRD1 P21728 1/20 0.53
HTT P42858 1/20 0.53
NFKB2 Q00653 1/20 0.53
RELA Q04206 1/20 0.53
HDAC6 Q9UBN7 1/20 0.53
HTR1A P08908 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8617302 0.88 RAB9A (0.63) RAB9ANPC1PKMSMN1; SMN2KMT2A
SCHEMBL1468602 0.83 RAB9A (0.60) RAB9ANPC1PKMSMN1; SMN2KMT2A
SCHEMBL9443968 0.83 NPC1 (0.52) RAB9ANPC1PKMSMN1; SMN2KMT2A
SCHEMBL10085912 0.81 NPC1 (0.66) RAB9ANPC1PKMSMN1; SMN2KMT2A
SCHEMBL28356779 0.80 NPC1 (0.68) RAB9ANPC1PKMSMN1; SMN2KMT2A
SCHEMBL4200619 0.80 NPC1 (0.67) RAB9ANPC1PKMSMN1; SMN2KMT2A
SCHEMBL6453869 0.79 NPC1 (0.57) RAB9ANPC1PKMSMN1; SMN2KMT2A
SCHEMBL28640863 0.78 NPC1 (0.62) RAB9ANPC1PKMSMN1; SMN2KMT2A
SCHEMBL8330483 0.78 RAB9A (0.60) RAB9ANPC1PKMSMN1; SMN2KMT2A
Methane SCHEMBL11254296 0.78 NPC1 (0.65) RAB9ANPC1PKMSMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof TAISHO PHARMACEUTICAL CO., LTD. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof HCRTR2, MCHR1, MCHR2 RAB9A 1648/4885NPC1 778/4885PKM 2145/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.